Coexistence of KRAS and BRAF mutations in colorectal cancer: a case report supporting the concept of tumoral heterogeneity
Cell Journal [Yakhteh]. 2017; 19 (Supp. 1): 113-117
in English
| IMEMR
| ID: emr-189347
ABSTRACT
The detection of KRAS and BRAF mutations is a crucial step for the correct therapeutic approach and predicting the epidermal growth factor receptor [EGFR]-targeted therapy resistance of colorectal carcinomas. The concomitant KRAS and BRAF mutations occur rarely in the colorectal cancers [CRCs] with the prevalence of less than 0.001% of the cases. In patients with KRAS-mutant tumors, BRAF mutations should not regularly be tested unless the patient is participating in a clinical trial enriching for the presence of KRAS or BRAF-mutated tumor. The current report demonstrates a case with advanced adenocarcinoma of the colon showing the coexistence of KRAS and BRAF mutations and may have profound clinical implications for disease progression and therapeutic responses
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Adenocarcinoma
/
Proto-Oncogene Proteins p21(ras)
/
Proto-Oncogene Proteins B-raf
/
ErbB Receptors
/
Mutation
Type of study:
Case report
Limits:
Humans
/
Male
Language:
English
Journal:
Cell J. [Yakhteh]
Year:
2017
Similar
MEDLINE
...
LILACS
LIS